Stay updated on Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial

Sign up to get notified when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in a study of pembrolizumab in combination with lenvatinib versus treatment of physician's choice for the treatment of advanced endometrial cancer, with the primary hypothesis being that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) compared to treatment of physician's choice.
    Difference
    0.1%
    Check dated 2024-06-06T14:36:13.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    23%
    Check dated 2024-05-22T21:29:20.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:35:37.000Z thumbnail image

Stay in the know with updates to Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.